I somewhat disagree about options being dead. Sure the $6-8 calls are probably off the table until 2018 but I am a bit intrigued by Dec 2017 $4 Calls. Last purchase was at $.20.
I believe we will hang out in the low $3's for a few weeks while people get over the fact that the trial continued. But then I think this stock will start to rise again. We could be back around $4 by mid to late Sept.
There is still 3rd Q ER which should be around early Nov and we should hear more about China/Middle East before end of year.
I think if these calls get a little cheaper, I may take a nibble because I believe they cannot keep this stock at these levels for very long...